Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Primary Objective: To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c) change from baseline to…
- Trial name
- LixiLan-O (NCT02058147)
- Testing
- Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010)
- Where
- 273 sites in United States, Australia and 21 more
- Volunteers
- 1,170 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
Primary Objective: To assess in healthy adult male subjects: The tolerability and safety of 21-day repeated subcutaneous (SC) doses of SAR425899 including two up titration steps.
- Trial name
- NCT02411825
- Testing
- SAR425899, metformin
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type2 Diabetes
DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients
An Open-Label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as Add-on Treatment in Type 2 Diabetes Mellitus (T2DM) Patients
- Trial name
- NCT03033433
- Testing
- DCB-DM101
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- VitNovo, Inc.
Non-Insulin-Dependent Diabetes Mellitus, Obesity
Efficacy and Safety of ATL-962 in Obese Diabetics
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
- Trial name
- NCT00156897
- Testing
- ATL-962, Orlistat
- Where
- 37 sites in Denmark, Finland and 3 more
- Volunteers
- 600 people
- Sponsor
- Alizyme
Type II Diabetes Mellitus
A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.
This study is a German, prospective, multicenter, controlled, cluster-randomized, interventional comparative study evaluating the efficacy and benefits of integrated PDM care by measuring HbA1c levels in patients with Type 2…
- Trial name
- PDMProValueDSP (NCT02156349)
- Testing
- Accu-Chek Smart Pix Software, Accu-Chek Smart Pix readout Device
- Where
- 50 sites in Germany
- Volunteers
- 558 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance
The purpose of the study is to determine whether a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients
- Trial name
- NCT00699790
- Testing
- CCR2 Antagonist
- Where
- 12 sites in Russia
- Volunteers
- 58 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast…
- Trial name
- NCT01340768
- Testing
- Sitagliptin, Sulfonylurea, Metformin
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.
This study will have a single arm: the patient on NPH will continue his treatment for 4 weeks, at the end of the NPH treatment, the patient will receive his CGM device for three days for glycemic holter, a switch to insulin…
- Trial name
- GRANT (NCT06999551)
- Testing
- switch NPH to glargin
- Where
- Tunisia
- Volunteers
- 60 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Diabetes Mellitus, Type 2
Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina
The DEAL (Diabetes En America Latina) study was a multicenter, cross-sectional, epidemiological, questionnaire based study carried out between October 2004 and October 2005 in 9 Latin American countries.
- Trial name
- DEAL (NCT01387165)
- Testing
- Treatment
- Volunteers
- 3,592 people
- Sponsor
- GlaxoSmithKline
Dyslipidemia/Glucose Metabolism Disorder
Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes
The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and…
- Trial name
- NCT00349128
- Testing
- fenofibrate and metformin combination (drug)
- Where
- 51 sites in Poland, Ukraine and 1 more
- Volunteers
- 382 people
- Sponsor
- Solvay Pharmaceuticals
Diabetes Mellitus, Type 2
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients…
- Trial name
- NCT01159600
- Testing
- BI 10773
- Where
- 148 sites in United States, Canada and 10 more
- Volunteers
- 1,504 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Self Titration With Apidra to Reach Target Study (START)
Primary Objective: The primary objective of this study is to demonstrate non-inferiority of a patient-managed titration algorithm (including blood glucose monitoring) for the addition of a single dose of insulin glulisine at…
- Trial name
- NCT01013571
- Testing
- insulin glargine, Apidra (insulin glulisine)
- Where
- Canada
- Volunteers
- 493 people
- Sponsor
- Sanofi
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or…
- Trial name
- DECLARE-TIMI58 (NCT01730534)
- Testing
- Dapagliflozin 10 mg
- Where
- 805 sites in United States, Argentina and 32 more
- Volunteers
- 17,190 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe
This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.
- Trial name
- NCT01890993
- Testing
- liraglutide
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 952 people
- Sponsor
- Novo Nordisk A/S
Diabetic Nephropathy
Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes
The primary objective of this study is to evaluate the efficacy of two different doses of Pyridorin (150 mg and 300 mg)compared to placebo in retarding the progression of diabetic nephropathy.
- Trial name
- NCT00734253
- Testing
- Pyridoxamine Dihydrochloride
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- NephroGenex, Inc.
Diabetes Mellitus, Type 2
A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine
The purpose of the study is to collect information on how the medicine Victoza® (liraglutide) works in people with Type 2 diabetes in Iran. Patients will get Victoza® as prescribed to them by their study doctor.
- Trial name
- VIEW-Iran (NCT03888157)
- Testing
- Liraglutide
- Where
- 16 sites in Iran
- Volunteers
- 839 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo
- Trial name
- NCT02583919
- Testing
- ISIS-GCGRRx- Dose Level 1, ISIS-GCGRRx- Dose Level 2
- Where
- 19 sites in United States
- Volunteers
- 79 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2, Atherosclerosis
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.
- Conditions
- Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
- Trial name
- NCT00995930
- Testing
- ACZ885
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin
The purpose of this study is to estimate the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and short-acting human insulin therapy within the first year following the switch.
- Trial name
- SWING (NCT00549887)
- Testing
- Analog or Human Insulin
- Where
- 27 sites in Austria, Czechia and 7 more
- Volunteers
- 2,459 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.